peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

6 Mar 2019, 08:00
Lund, Sweden, March 6, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present at the Cowen 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 9:20AM ET/ 3:20PM CET. The conference will be held at the Boston Marriott Copley Place in Boston, MA. 

A live webcast will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation. 

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on March 6, 2019.  

Files

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ)
Mobile: +46 707 175477
E-mail: emanuel.bjorne@hansabiopharma.com

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1 212 600 1902

About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm:HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.